Search research articles
Contact Us
Filters
Showing results (1-10 of 136) with videos related to
Page
of 14
Sort By:
Expert Opinion on Therapeutic Patents
|
April 27, 2019
A patent review of bisphosphonates in treating bone disease
Sarah A Holstein
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma
Sarah A Holstein
JCO Oncology Practice
|
February 12, 2020
Autologous Stem-Cell Transplantation for Myeloma: Here to Stay?
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
May 19, 2025
A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
January 17, 2025
Leveraging Real-World Data to Address Potential Methadone Drug-Drug Interactions
Sarah A Holstein
Oncology (Williston Park, N.Y.)
|
July 18, 2022
Current Frontline Treatment of Multiple Myeloma
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
November 10, 2025
Home Is Where the Research Is: The Promise of Decentralized Clinical Trials
Sarah A Holstein
Drugs of Today (Barcelona, Spain : 1998)
|
February 22, 2023
Ciltacabtagene autoleucel for the treatment of multiple myeloma
Sarah A Holstein
Journal of Oncology Practice
|
July 12, 2018
Present and Future of Immunotherapy in the Management of Multiple Myeloma
Muhamed Baljevic, Sarah A Holstein
Expert Review of Clinical Pharmacology
|
January 21, 2022
The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes
Meghana Kesireddy, Sarah A Holstein
Page
of 14
Search research articles
Search
Showing results (1-10 of 136) with videos related to
Sort By:
Page
of 14
Expert Opinion on Therapeutic Patents
|
April 27, 2019
A patent review of bisphosphonates in treating bone disease
Sarah A Holstein
Hematology. American Society of Hematology. Education Program
|
December 9, 2022
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma
Sarah A Holstein
JCO Oncology Practice
|
February 12, 2020
Autologous Stem-Cell Transplantation for Myeloma: Here to Stay?
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
May 19, 2025
A Reflection on the Evolution of Antibody-Based Therapies in Oncology: Trastuzumab as an Exemplar-Commentary on Dijkers et al
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
January 17, 2025
Leveraging Real-World Data to Address Potential Methadone Drug-Drug Interactions
Sarah A Holstein
Oncology (Williston Park, N.Y.)
|
July 18, 2022
Current Frontline Treatment of Multiple Myeloma
Sarah A Holstein
Clinical Pharmacology and Therapeutics
|
November 10, 2025
Home Is Where the Research Is: The Promise of Decentralized Clinical Trials
Sarah A Holstein
Drugs of Today (Barcelona, Spain : 1998)
|
February 22, 2023
Ciltacabtagene autoleucel for the treatment of multiple myeloma
Sarah A Holstein
Journal of Oncology Practice
|
July 12, 2018
Present and Future of Immunotherapy in the Management of Multiple Myeloma
Muhamed Baljevic, Sarah A Holstein
Expert Review of Clinical Pharmacology
|
January 21, 2022
The era of lenalidomide maintenance therapy in multiple myeloma: settings for achieving best outcomes
Meghana Kesireddy, Sarah A Holstein
Page
of 14